{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:03:27Z","timestamp":1788897807124,"version":"build-2803163510"},"reference-count":118,"publisher":"Zhejiang University Press","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Zhejiang Univ. Sci. B"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1631\/jzus.b2500789","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:04:27Z","timestamp":1785830667000},"page":"736-760","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in biomarkers for Parkinson\u2019s disease: from molecular pathology to precision diagnostics","\u5e15\u91d1\u68ee\u75c5\u751f\u7269\u6807\u5fd7\u7269\u7814\u7a76\u8fdb\u5c55: \u4ece\u5206\u5b50\u75c5\u7406\u5230\u7cbe\u51c6\u8bca\u65ad"],"prefix":"10.1631","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9209-5046","authenticated-orcid":false,"given":"Xiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2179-8742","authenticated-orcid":false,"given":"Honglin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhe","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-5567","authenticated-orcid":false,"given":"Zhaofei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3096-1609","authenticated-orcid":false,"given":"Min","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"635","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"issue":"12","key":"854_CR1","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/mds.28779","volume":"36","author":"WW Aamodt","year":"2021","unstructured":"Aamodt WW, Waligorska T, Shen JC, et al., 2021. Neurofilament light chain as a biomarker for cognitive decline in Parkinson disease. Mov Disord, 36(12):2945\u20132950. https:\/\/doi.org\/10.1002\/mds.28779","journal-title":"Mov Disord"},{"issue":"8","key":"854_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S1474-4422(25)00194-2","volume":"24","author":"J Agin-Liebes","year":"2025","unstructured":"Agin-Liebes J, Lodge A, Reddy H, et al., 2025. \u03b1-Synuclein biomarker assays: bridging research and patient care. Lancet Neurol, 24(8):681\u2013697. https:\/\/doi.org\/10.1016\/s1474-4422(25)00194-2","journal-title":"Lancet Neurol"},{"key":"854_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40035-024-00421-0","volume":"13","author":"E Appleton","year":"2024","unstructured":"Appleton E, Khosousi S, Ta M, et al., 2024. DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson\u2019s disease. Transl Neurodegener, 13:31. https:\/\/doi.org\/10.1186\/s40035-024-00421-0","journal-title":"Transl Neurodegener"},{"issue":"3","key":"854_CR4","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bpa.12370","volume":"26","author":"A Atik","year":"2016","unstructured":"Atik A, Stewart T, Zhang J, 2016. Alpha-synuclein as a biomarker for Parkinson\u2019s disease. Brain Pathol, 26(3):410\u2013418. https:\/\/doi.org\/10.1111\/bpa.12370","journal-title":"Brain Pathol"},{"issue":"7","key":"854_CR5","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1212\/WNL.0000000000010084","volume":"95","author":"D B\u00e4ckstr\u00f6m","year":"2020","unstructured":"B\u00e4ckstr\u00f6m D, Linder J, Jakobson Mo S, et al., 2020. NfL as a biomarker for neurodegeneration and survival in Parkinson disease. Neurology, 95(7):e827\u2013e838. https:\/\/doi.org\/10.1212\/wnl.0000000000010084","journal-title":"Neurology"},{"issue":"3","key":"854_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00259-015-3176-5","volume":"43","author":"S Badoud","year":"2016","unstructured":"Badoud S, Nicastro N, Garibotto V, et al., 2016. Distinct spatiotemporal patterns for disease duration and stage in Parkinson\u2019s disease. Eur J Nucl Med Mol Imaging, 43(3): 509\u2013516. https:\/\/doi.org\/10.1007\/s00259-015-3176-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"854_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000112832","volume":"5","author":"R Barbour","year":"2008","unstructured":"Barbour R, Kling K, Anderson JP, et al., 2008. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis, 5(2):55\u201359. https:\/\/doi.org\/10.1159\/000112832","journal-title":"Neurodegener Dis"},{"key":"854_CR8","doi-asserted-by":"publisher","first-page":"105744","DOI":"10.1016\/j.nbd.2022.105744","volume":"170","author":"M Bartl","year":"2022","unstructured":"Bartl M, Xylaki M, B\u00e4hr M, et al., 2022. Evidence for immune system alterations in peripheral biological fluids in Parkinson\u2019s disease. Neurobiol Dis, 170:105744. https:\/\/doi.org\/10.1016\/j.nbd.2022.105744","journal-title":"Neurobiol Dis"},{"issue":"5","key":"854_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1212\/WNL.0000000000200878","volume":"99","author":"G Bellomo","year":"2022","unstructured":"Bellomo G, de Luca CMG, Paoletti FP, et al., 2022. \u03b1-Synuclein seed amplification assays for diagnosing synucleinopathies: the way forward. Neurology, 99(5):195\u2013205. https:\/\/doi.org\/10.1212\/wnl.0000000000200878","journal-title":"Neurology"},{"issue":"6","key":"854_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41582-021-00486-9","volume":"17","author":"D Berg","year":"2021","unstructured":"Berg D, Borghammer P, Fereshtehnejad SM, et al., 2021. Prodromal Parkinson disease subtypes \u2013 key to understanding heterogeneity. Nat Rev Neurol, 17(6):349\u2013361. https:\/\/doi.org\/10.1038\/s41582-021-00486-9","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"854_CR11","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","volume":"19","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat C, Nalls MA, Singleton AB, 2020. The genetic architecture of Parkinson\u2019s disease. Lancet Neurol, 19(2): 170\u2013178. https:\/\/doi.org\/10.1016\/s1474-4422(19)30287-x","journal-title":"Lancet Neurol"},{"issue":"10","key":"854_CR12","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1093\/brain\/awaa246","volume":"143","author":"M Borsche","year":"2020","unstructured":"Borsche M, K\u00f6nig IR, Delcambre S, et al., 2020. Mitochondrial damage-associated inflammation highlights biomarkers in PRKN\/PINK1 parkinsonism. Brain, 143(10):3041\u20133051. https:\/\/doi.org\/10.1093\/brain\/awaa246","journal-title":"Brain"},{"issue":"2","key":"854_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, del Tredici K, R\u00fcb U, et al., 2003. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging, 24(2):197\u2013211. https:\/\/doi.org\/10.1016\/s0197-4580(02)00065-9","journal-title":"Neurobiol Aging"},{"key":"854_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13024-025-00868-3","volume":"20","author":"M Bregendahl","year":"2025","unstructured":"Bregendahl M, Kaya ZB, Singer W, et al., 2025. Alpha-synuclein seeding amplification assays in Lewy body dementia: a brief review. Mol Neurodegener, 20:77. https:\/\/doi.org\/10.1186\/s13024-025-00868-3","journal-title":"Mol Neurodegener"},{"key":"854_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41746-024-01236-z","volume":"7","author":"C Brzenczek","year":"2024","unstructured":"Brzenczek C, Klopfenstein Q, H\u00e4hnel T, et al., 2024. Integrating digital gait data with metabolomics and clinical data to predict outcomes in Parkinson\u2019s disease. NPJ Digit Med, 7:235. https:\/\/doi.org\/10.1038\/s41746-024-01236-z","journal-title":"NPJ Digit Med"},{"key":"854_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s40478-025-02034-8","volume":"13","author":"R Bsoul","year":"2025","unstructured":"Bsoul R, McWilliam OH, Waldemar G, et al., 2025. Accurate detection of pathologic \u03b1-synuclein in CSF, skin, olfactory mucosa, and urine with a uniform seeding amplification assay. Acta Neuropathol Commun, 13:113. https:\/\/doi.org\/10.1186\/s40478-025-02034-8","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"854_CR17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/mds.29329","volume":"38","author":"L Concha-Marambio","year":"2023","unstructured":"Concha-Marambio L, Weber S, Farris CM, et al., 2023a. Accurate detection of \u03b1-synuclein seeds in cerebrospinal fluid from isolated rapid eye movement sleep behavior disorder and patients with Parkinson\u2019s disease in the denovo Parkinson (DeNoPa) cohort. Mov Disord, 38(4):567\u2013578. https:\/\/doi.org\/10.1002\/mds.29329","journal-title":"Mov Disord"},{"issue":"4","key":"854_CR18","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41596-022-00787-3","volume":"18","author":"L Concha-Marambio","year":"2023","unstructured":"Concha-Marambio L, Pritzkow S, Shahnawaz M, et al., 2023b. Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. Nat Protoc, 18(4):1179\u20131196. https:\/\/doi.org\/10.1038\/s41596-022-00787-3","journal-title":"Nat Protoc"},{"issue":"6","key":"854_CR19","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/brain\/awae404","volume":"148","author":"A Cort\u00e9s","year":"2025","unstructured":"Cort\u00e9s A, Phung TK, de Mena L, et al., 2025. In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson\u2019s disease. Brain, 148(6):2075\u20132092. https:\/\/doi.org\/10.1093\/brain\/awae404","journal-title":"Brain"},{"issue":"5","key":"854_CR20","doi-asserted-by":"publisher","first-page":"e210279","DOI":"10.1212\/WNL.0000000000210279","volume":"104","author":"DG Coughlin","year":"2025","unstructured":"Coughlin DG, Shifflett B, Farris CM, et al., 2025. \u03b1-Synuclein seed amplification assay amplification parameters and the risk of progression in prodromal Parkinson disease. Neurology, 104(5):e210279. https:\/\/doi.org\/10.1212\/wnl.0000000000210279","journal-title":"Neurology"},{"issue":"1","key":"854_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/mds.27569","volume":"34","author":"SS Cui","year":"2019","unstructured":"Cui SS, Du JJ, Liu SH, et al., 2019. Serum soluble lymphocyte activation gene-3 as a diagnostic biomarker in Parkinson\u2019s disease: a pilot multicenter study. Mov Disord, 34(1):138\u2013141. https:\/\/doi.org\/10.1002\/mds.27569","journal-title":"Mov Disord"},{"issue":"12","key":"854_CR22","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.4103\/NRR.NRR-D-23-01677","volume":"19","author":"MI de Bartolo","year":"2024","unstructured":"de Bartolo MI, Belvisi D, Mancinelli R, et al., 2024. A systematic review of salivary biomarkers in Parkinson\u2019s disease. Neural Regen Res, 19(12):2613\u20132625. https:\/\/doi.org\/10.4103\/nrr.Nrr-d-23-01677","journal-title":"Neural Regen Res"},{"key":"854_CR23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41531-024-00671-9","volume":"10","author":"EG de Lope","year":"2024","unstructured":"de Lope EG, Loo RTJ, Rauschenberger A, et al., 2024. Comprehensive blood metabolomics profiling of Parkinson\u2019s disease reveals coordinated alterations in xanthine metabolism. NPJ Parkinson\u2019s Dis, 10:68. https:\/\/doi.org\/10.1038\/s41531-024-00671-9","journal-title":"NPJ Parkinson\u2019s Dis"},{"issue":"5","key":"854_CR24","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/mds.29360","volume":"38","author":"JM den Heijer","year":"2023","unstructured":"den Heijer JM, Cullen VC, Pereira DR, et al., 2023. A bio-marker study in patients with GBA1-Parkinson\u2019s disease and healthy controls. Mov Disord, 38(5):783\u2013795. https:\/\/doi.org\/10.1002\/mds.29360","journal-title":"Mov Disord"},{"key":"854_CR25","doi-asserted-by":"publisher","first-page":"106986","DOI":"10.1016\/j.parkreldis.2024.106986","volume":"126","author":"AGP Dennis","year":"2024","unstructured":"Dennis AGP, Strafella AP, 2024. The role of AI and machine learning in the diagnosis of Parkinson\u2019s disease and atypical parkinsonisms. Parkinsonism Relat Disord, 126: 106986. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106986","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"854_CR26","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/jcbfm.1994.99","volume":"14","author":"D Eidelberg","year":"1994","unstructured":"Eidelberg D, Moeller JR, Dhawan V, et al., 1994. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab, 14(5):783\u2013801. https:\/\/doi.org\/10.1038\/jcbfm.1994.99","journal-title":"J Cereb Blood Flow Metab"},{"issue":"10","key":"854_CR27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrneurol.2009.135","volume":"5","author":"M Eller","year":"2009","unstructured":"Eller M, Williams DR, 2009. Biological fluid biomarkers in neurodegenerative parkinsonism. Nat Rev Neurol, 5(10): 561\u2013570. https:\/\/doi.org\/10.1038\/nrneurol.2009.135","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"854_CR28","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/mds.27110","volume":"32","author":"P Eusebi","year":"2017","unstructured":"Eusebi P, Giannandrea D, Biscetti L, et al., 2017. Diagnostic utility of cerebrospinal fluid \u03b1-synuclein in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord, 32(10):1389\u20131400. https:\/\/doi.org\/10.1002\/mds.27110","journal-title":"Mov Disord"},{"issue":"10","key":"854_CR29","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1093\/brain\/awac176","volume":"145","author":"J Galper","year":"2022","unstructured":"Galper J, Dean NJ, Pickford R, et al., 2022. Lipid pathway dysfunction is prevalent in patients with Parkinson\u2019s disease. Brain, 145(10):3472\u20133487. https:\/\/doi.org\/10.1093\/brain\/awac176","journal-title":"Brain"},{"issue":"9","key":"854_CR30","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3109\/00207454.2014.961454","volume":"125","author":"L Gao","year":"2015","unstructured":"Gao L, Tang HM, Nie K, et al., 2015. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson\u2019s disease diagnosis: a systematic review and meta-analysis. Int J Neurosci, 125(9):645\u2013654. https:\/\/doi.org\/10.3109\/00207454.2014.961454","journal-title":"Int J Neurosci"},{"issue":"15","key":"854_CR31","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1001\/jama.2024.0792","volume":"331","author":"CH Gibbons","year":"2024","unstructured":"Gibbons CH, Levine T, Adler C, et al., 2024. Skin biopsy detection of phosphorylated \u03b1-synuclein in patients with synucleinopathies. JAMA, 331(15):1298\u20131306. https:\/\/doi.org\/10.1001\/jama.2024.0792","journal-title":"JAMA"},{"issue":"8","key":"854_CR32","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(23)00205-3","volume":"22","author":"N Giladi","year":"2023","unstructured":"Giladi N, Alcalay RN, Cutter G, et al., 2023. Safety and efficacy of venglustat in GBA1-associated Parkinson\u2019s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol, 22(8): 661\u2013671. https:\/\/doi.org\/10.1016\/s1474-4422(23)00205-3","journal-title":"Lancet Neurol"},{"issue":"45","key":"854_CR33","doi-asserted-by":"publisher","first-page":"e2408949121","DOI":"10.1073\/pnas.2408949121","volume":"121","author":"T Gilboa","year":"2024","unstructured":"Gilboa T, Ter-Ovanesyan D, Wang SC, et al., 2024. Measurement of \u03b1-synuclein as protein cargo in plasma extracellular vesicles. Proc Natl Acad Sci USA, 121(45):e2408949121. https:\/\/doi.org\/10.1073\/pnas.2408949121","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"854_CR34","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.parkreldis.2007.04.003","volume":"13","author":"MC Gonz\u00e1lez-Fern\u00e1ndez","year":"2007","unstructured":"Gonz\u00e1lez-Fern\u00e1ndez MC, Lezcano E, Ross OA, et al., 2007. Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. Parkinsonism Relat Disord, 13(8): 509\u2013515. https:\/\/doi.org\/10.1016\/j.parkreldis.2007.04.003","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"854_CR35","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/ana.26923","volume":"95","author":"P Gonzalez-Latapi","year":"2024","unstructured":"Gonzalez-Latapi P, Bustos B, Dong SY, et al., 2024. Alterations in blood methylome as potential epigenetic biomarker in sporadic Parkinson\u2019s disease. Ann Neurol, 95(6): 1162\u20131172. https:\/\/doi.org\/10.1002\/ana.26923","journal-title":"Ann Neurol"},{"issue":"2","key":"854_CR36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/mds.30085","volume":"40","author":"P Grillo","year":"2025","unstructured":"Grillo P, Concha-Marambio L, Pisani A, et al., 2025. Association between the amplification parameters of the \u03b1-synuclein seed amplification assay and clinical and genetic subtypes of Parkinson\u2019s disease. Mov Disord, 40(2):305\u2013314. https:\/\/doi.org\/10.1002\/mds.30085","journal-title":"Mov Disord"},{"issue":"5","key":"854_CR37","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1093\/brain\/awaa090","volume":"143","author":"M Guo","year":"2020","unstructured":"Guo M, Wang J, Zhao YX, et al., 2020. Microglial exosomes facilitate \u03b1-synuclein transmission in Parkinson\u2019s disease. Brain, 143(5):1476\u20131497. https:\/\/doi.org\/10.1093\/brain\/awaa090","journal-title":"Brain"},{"issue":"1","key":"854_CR38","doi-asserted-by":"publisher","first-page":"e242044","DOI":"10.1148\/radiol.242044","volume":"317","author":"S Haller","year":"2025","unstructured":"Haller S, He NY, Schwarz S, et al., 2025. Clinical MRI bio-markers to differentiate Parkinson disease from its mimics. Radiology, 317(1):e242044. https:\/\/doi.org\/10.1148\/radiol.242044","journal-title":"Radiology"},{"issue":"10","key":"854_CR39","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson O, Janelidze S, Hall S, et al., 2017. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology, 88(10):930\u2013937. https:\/\/doi.org\/10.1212\/wnl.0000000000003680","journal-title":"Neurology"},{"key":"854_CR40","doi-asserted-by":"publisher","first-page":"117810","DOI":"10.1016\/j.neuroimage.2021.117810","volume":"230","author":"NY He","year":"2021","unstructured":"He NY, Ghassaban K, Huang P, et al., 2021. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson\u2019s disease. Neuroimage, 230:117810. https:\/\/doi.org\/10.1016\/j.neuroimage.2021.117810","journal-title":"Neuroimage"},{"issue":"1","key":"854_CR41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.5582\/bst.2024.01369","volume":"19","author":"CT Hong","year":"2025","unstructured":"Hong CT, Chung CC, Hsieh YC, et al., 2025. Plasma extracellular vesicle pathognomonic proteins as the biomarkers of the progression of Parkinson\u2019s disease. Biosci Trends, 19(1):116\u2013124. https:\/\/doi.org\/10.5582\/bst.2024.01369","journal-title":"Biosci Trends"},{"issue":"9","key":"854_CR42","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1631\/jzus.B2400186","volume":"26","author":"XD Huang","year":"2025","unstructured":"Huang XD, Fang Y, Song J, et al., 2025. Rescuing lysosomal\/autophagic defects via nanoapproach: implications for lysosomal\/autophagic defect-related diseases. J Zhejiang Univ-Sci B, 26(9):813\u2013842. https:\/\/doi.org\/10.1631\/jzus.B2400186","journal-title":"J Zhejiang Univ-Sci B"},{"issue":"9","key":"854_CR43","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1474-4422(11)70152-1","volume":"10","author":"A Iranzo","year":"2011","unstructured":"Iranzo A, Valldeoriola F, Lome\u00f1a F, et al., 2011. Serial dopa-mine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol, 10(9): 797\u2013805. https:\/\/doi.org\/10.1016\/s1474-4422(11)70152-1","journal-title":"Lancet Neurol"},{"issue":"18","key":"854_CR44","doi-asserted-by":"publisher","first-page":"e1944","DOI":"10.1212\/WNL.0000000000207147","volume":"100","author":"A Iranzo","year":"2023","unstructured":"Iranzo A, Mammana A, Mu\u00f1oz-Lopetegi A, et al., 2023. Misfolded \u03b1-synuclein assessment in the skin and CSF by RT-QuIC in isolated REM sleep behavior disorder. Neurology, 100(18):e1944\u2013e1954. https:\/\/doi.org\/10.1212\/wnl.0000000000207147","journal-title":"Neurology"},{"issue":"3","key":"854_CR45","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ana.25811","volume":"88","author":"DJ Irwin","year":"2020","unstructured":"Irwin DJ, Fedler J, Coffey CS, et al., 2020. Evolution of Alzheimer\u2019s disease cerebrospinal fluid biomarkers in early Parkinson\u2019s disease. Ann Neurol, 88(3):574\u2013587. https:\/\/doi.org\/10.1002\/ana.25811","journal-title":"Ann Neurol"},{"issue":"4","key":"854_CR46","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00702-018-1898-9","volume":"126","author":"KA Jellinger","year":"2019","unstructured":"Jellinger KA, 2019. Is Braak staging valid for all types of Parkinson\u2019s disease? J Neural Transm, 126(4):423\u2013431. https:\/\/doi.org\/10.1007\/s00702-018-1898-9","journal-title":"J Neural Transm"},{"issue":"7","key":"854_CR47","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/jnnp-2019-322588","volume":"91","author":"C Jiang","year":"2020","unstructured":"Jiang C, Hopfner F, Katsikoudi A, et al., 2020. Serum neuronal exosomes predict and differentiate Parkinson\u2019s disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry, 91(7):720\u2013729. https:\/\/doi.org\/10.1136\/jnnp-2019-322588","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9996","key":"854_CR48","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE, 2015. Parkinson\u2019s disease. Lancet, 386(9996): 896\u2013912. https:\/\/doi.org\/10.1016\/s0140-6736(14)61393-3","journal-title":"Lancet"},{"issue":"6","key":"854_CR49","doi-asserted-by":"publisher","first-page":"100661","DOI":"10.1016\/j.xcrm.2022.100661","volume":"3","author":"O Karayel","year":"2022","unstructured":"Karayel O, Virreira Winter S, Padmanabhan S, et al., 2022. Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinson\u2019s disease. Cell Rep Med, 3(6): 100661. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100661","journal-title":"Cell Rep Med"},{"issue":"3","key":"854_CR50","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3233\/JPD-201965","volume":"10","author":"R Kayed","year":"2020","unstructured":"Kayed R, Dettmer U, Lesn\u00e9 SE, 2020. Soluble endogenous oligomeric \u03b1-synuclein species in neurodegenerative diseases: expression, spreading, and cross-talk. J Parkinsons Dis, 10(3):791\u2013818. https:\/\/doi.org\/10.3233\/jpd-201965","journal-title":"J Parkinsons Dis"},{"issue":"8","key":"854_CR51","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/mds.29766","volume":"39","author":"A Kluge","year":"2024","unstructured":"Kluge A, Schaeffer E, Bunk J, et al., 2024. Detecting misfolded \u03b1-synuclein in blood years before the diagnosis of Parkinson\u2019s disease. Mov Disord, 39(8):1289\u20131299. https:\/\/doi.org\/10.1002\/mds.29766","journal-title":"Mov Disord"},{"key":"854_CR52","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.bbi.2022.01.005","volume":"101","author":"S Konstantin Nissen","year":"2022","unstructured":"Konstantin Nissen S, Farmen K, Carstensen M, et al., 2022. Changes in CD163, CD11b, and CCR2 peripheral monocytes relate to Parkinson\u2019s disease and cognition. Brain Behav Immun, 101:182\u2013193. https:\/\/doi.org\/10.1016\/j.bbi.2022.01.005","journal-title":"Brain Behav Immun"},{"key":"854_CR53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41531-021-00242-2","volume":"7","author":"A Kuzkina","year":"2021","unstructured":"Kuzkina A, Bargar C, Schmitt D, et al., 2021. Diagnostic value of skin RT-QuIC in Parkinson\u2019s disease: a two-laboratory study. npj Parkinsons Dis, 7:99. https:\/\/doi.org\/10.1038\/s41531-021-00242-2","journal-title":"npj Parkinsons Dis"},{"issue":"2","key":"854_CR54","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/mds.27888","volume":"35","author":"M Lawton","year":"2020","unstructured":"Lawton M, Baig F, Toulson G, et al., 2020. Blood biomarkers with Parkinson\u2019s disease clusters and prognosis: the oxford discovery cohort. Mov Disord, 35(2):279\u2013287. https:\/\/doi.org\/10.1002\/mds.27888","journal-title":"Mov Disord"},{"issue":"4","key":"854_CR55","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMc055540","volume":"354","author":"S Lesage","year":"2006","unstructured":"Lesage S, D\u00fcrr A, Tazir M, et al., 2006. LRRK2 G2019S as a cause of Parkinson\u2019s disease in North African Arabs. N Engl J Med, 354(4):422\u2013423. https:\/\/doi.org\/10.1056\/NEJMc055540","journal-title":"N Engl J Med"},{"issue":"11","key":"854_CR56","doi-asserted-by":"publisher","first-page":"e1104","DOI":"10.1212\/WNL.0000000000008088","volume":"93","author":"CH Lin","year":"2019","unstructured":"Lin CH, Li CH, Yang KC, et al., 2019. Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology, 93(11):e1104\u2013e1111. https:\/\/doi.org\/10.1212\/wnl.0000000000008088","journal-title":"Neurology"},{"key":"854_CR57","doi-asserted-by":"publisher","first-page":"102658","DOI":"10.1016\/j.arr.2025.102658","volume":"104","author":"N Liu","year":"2025","unstructured":"Liu N, Zhang TJ, Zhao W, et al., 2025. Current trends in blood biomarkers detection and neuroimaging for Parkinson\u2019s disease. Ageing Res Rev, 104:102658. https:\/\/doi.org\/10.1016\/j.arr.2025.102658","journal-title":"Ageing Res Rev"},{"issue":"6109","key":"854_CR58","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","volume":"338","author":"KC Luk","year":"2012","unstructured":"Luk KC, Kehm V, Carroll J, et al., 2012. Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science, 338(6109): 949\u2013953. https:\/\/doi.org\/10.1126\/science.1227157","journal-title":"Science"},{"issue":"4","key":"854_CR59","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/mds.26932","volume":"32","author":"P Mahlknecht","year":"2017","unstructured":"Mahlknecht P, Krismer F, Poewe W, et al., 2017. Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson\u2019s disease. Mov Disord, 32(4):619\u2013623. https:\/\/doi.org\/10.1002\/mds.26932","journal-title":"Mov Disord"},{"key":"854_CR60","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13024-016-0072-9","volume":"11","author":"NK Majbour","year":"2016","unstructured":"Majbour NK, Vaikath NN, van Dijk KD, et al., 2016. Oligomeric and phosphorylated alpha-synuclein as potential CSF bio-markers for Parkinson\u2019s disease. Mol Neurodegener, 11:7. https:\/\/doi.org\/10.1186\/s13024-016-0072-9","journal-title":"Mol Neurodegener"},{"issue":"13","key":"854_CR61","doi-asserted-by":"publisher","first-page":"e1479","DOI":"10.1212\/WNL.0000000000007179","volume":"92","author":"TM Marques","year":"2019","unstructured":"Marques TM, van Rumund A, Oeckl P, et al., 2019. Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology, 92(13):e1479\u2013e1486. https:\/\/doi.org\/10.1212\/wnl.0000000000007179","journal-title":"Neurology"},{"issue":"8","key":"854_CR62","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1474-4422(21)00176-9","volume":"20","author":"MG Miglis","year":"2021","unstructured":"Miglis MG, Adler CH, Antelmi E, et al., 2021. Biomarkers of conversion to \u03b1-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurol, 20(8): 671\u2013684. https:\/\/doi.org\/10.1016\/s1474-4422(21)00176-9","journal-title":"Lancet Neurol"},{"issue":"10","key":"854_CR63","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1001\/jamaneurol.2021.1312","volume":"78","author":"T Mitchell","year":"2021","unstructured":"Mitchell T, Leh\u00e9ricy S, Chiu SY, et al., 2021. Emerging neuroimaging biomarkers across disease stage in Parkinson disease: a review. JAMA Neurol, 78(10):1262\u20131272. https:\/\/doi.org\/10.1001\/jamaneurol.2021.1312","journal-title":"JAMA Neurol"},{"issue":"11","key":"854_CR64","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1002\/mds.28206","volume":"35","author":"B Mollenhauer","year":"2020","unstructured":"Mollenhauer B, Dakna M, Kruse N, et al., 2020. Validation of serum neurofilament light chain as a biomarker of Parkinson\u2019s disease progression. Mov Disord, 35(11): 1999\u20132008. https:\/\/doi.org\/10.1002\/mds.28206","journal-title":"Mov Disord"},{"issue":"15","key":"854_CR65","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/mds.23287","volume":"25","author":"TJ Montine","year":"2010","unstructured":"Montine TJ, Shi M, Quinn JF, et al., 2010. CSF A\u03b242 and tau in Parkinson\u2019s disease with cognitive impairment. Mov Disord, 25(15):2682\u20132685. https:\/\/doi.org\/10.1002\/mds.23287","journal-title":"Mov Disord"},{"key":"854_CR66","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41531-024-00770-7","volume":"10","author":"A Mu\u00f1oz-Lopetegi","year":"2024","unstructured":"Mu\u00f1oz-Lopetegi A, Baiardi S, Balasa M, et al., 2024. CSF markers of neurodegeneration Alzheimer\u2019s and Lewy body pathology in isolated REM sleep behavior disorder. npj Parkinsons Dis, 10:157. https:\/\/doi.org\/10.1038\/s41531-024-00770-7","journal-title":"npj Parkinsons Dis"},{"issue":"1","key":"854_CR67","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/ana.27250","volume":"98","author":"L M\u00fcller","year":"2025","unstructured":"M\u00fcller L, \u00d6zd\u00fczenciler P, Schedlich-Teufer C, et al., 2025. Elevated \u03b1-synuclein aggregate levels in the urine of patients with isolated REM sleep behavior disorder and Parkinson\u2019s disease. Ann Neurol, 98(1):147\u2013151. https:\/\/doi.org\/10.1002\/ana.27250","journal-title":"Ann Neurol"},{"key":"854_CR68","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.parkreldis.2018.06.025","volume":"56","author":"GW O\u2019Keeffe","year":"2018","unstructured":"O\u2019Keeffe GW, Sullivan AM, 2018. Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson\u2019s disease. Parkinsonism Relat Disord, 56:9\u201315. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.06.025","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"854_CR69","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","volume":"29","author":"A Okuzumi","year":"2023","unstructured":"Okuzumi A, Hatano T, Matsumoto G, et al., 2023. Propagative \u03b1-synuclein seeds as serum biomarkers for synucle-inopathies. Nat Med, 29(6):1448\u20131455. https:\/\/doi.org\/10.1038\/s41591-023-02358-9","journal-title":"Nat Med"},{"issue":"2","key":"854_CR70","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/mds.27897","volume":"35","author":"LP Oosterveld","year":"2020","unstructured":"Oosterveld LP, Verberk IMW, Majbour NK, et al., 2020. CSF or serum neurofilament light added to \u03b1-synuclein panel discriminates Parkinson\u2019s from controls. Mov Disord, 35(2):288\u2013295. https:\/\/doi.org\/10.1002\/mds.27897","journal-title":"Mov Disord"},{"issue":"4","key":"854_CR71","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMc055509","volume":"354","author":"LJ Ozelius","year":"2006","unstructured":"Ozelius LJ, Senthil G, Saunders-Pullman R, et al., 2006. LRRK2 G2019S as a cause of Parkinson\u2019s disease in Ashkenazi Jews. N Engl J Med, 354(4):424\u2013425. https:\/\/doi.org\/10.1056\/NEJMc055509","journal-title":"N Engl J Med"},{"issue":"6","key":"854_CR72","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti L, Gaetani L, Eusebi P, et al., 2019. CSF and blood biomarkers for Parkinson\u2019s disease. Lancet Neurol, 18(6): 573\u2013586. https:\/\/doi.org\/10.1016\/s1474-4422(19)30024-9","journal-title":"Lancet Neurol"},{"key":"854_CR73","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-023-00374-w","volume":"12","author":"W Paslawski","year":"2023","unstructured":"Paslawski W, Khosousi S, Hertz E, et al., 2023. Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson\u2019s disease. Transl Neurodegener, 12:42. https:\/\/doi.org\/10.1186\/s40035-023-00374-w","journal-title":"Transl Neurodegener"},{"issue":"7706","key":"854_CR74","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-018-0104-4","volume":"557","author":"C Peng","year":"2018","unstructured":"Peng C, Gathagan RJ, Covell DJ, et al., 2018. Cellular milieu imparts distinct pathological \u03b1-synuclein strains in \u03b1-synucleinopathies. Nature, 557(7706):558\u2013563. https:\/\/doi.org\/10.1038\/s41586-018-0104-4","journal-title":"Nature"},{"issue":"4","key":"854_CR75","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/mds.26073","volume":"30","author":"L Pihlstr\u00f8m","year":"2015","unstructured":"Pihlstr\u00f8m L, Berge V, Rengmark A, et al., 2015. Parkinson\u2019s disease correlates with promoter methylation in the \u03b1-synuclein gene. Mov Disord, 30(4):577\u2013580. https:\/\/doi.org\/10.1002\/mds.26073","journal-title":"Mov Disord"},{"issue":"4","key":"854_CR76","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1021\/acscentsci.9b00319","volume":"5","author":"W Poewe","year":"2019","unstructured":"Poewe W, 2019. Smelling Parkinson\u2019s disease: new metabolomic biomarker for PD. ACS Cent Sci, 5(4):575\u2013576. https:\/\/doi.org\/10.1021\/acscentsci.9b00319","journal-title":"ACS Cent Sci"},{"issue":"5321","key":"854_CR77","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, et al., 1997. Mutation in the \u03b1-synuclein gene identified in families with Parkinson\u2019s disease. Science, 276(5321):2045\u20132047. https:\/\/doi.org\/10.1126\/science.276.5321.2045","journal-title":"Science"},{"issue":"10","key":"854_CR78","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/mds.26347","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Adler CH, Dugger BN, et al., 2015. REM sleep behavior disorder and neuropathology in Parkinson\u2019s disease. Mov Disord, 30(10):1413\u20131417. https:\/\/doi.org\/10.1002\/mds.26347","journal-title":"Mov Disord"},{"issue":"3","key":"854_CR79","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/brain\/awz030","volume":"142","author":"RB Postuma","year":"2019","unstructured":"Postuma RB, Iranzo A, Hu M, et al., 2019. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain, 142(3): 744\u2013759. https:\/\/doi.org\/10.1093\/brain\/awz030","journal-title":"Brain"},{"issue":"5","key":"854_CR80","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1093\/brain\/awac414","volume":"146","author":"R Real","year":"2023","unstructured":"Real R, Martinez-Carrasco A, Reynolds RH, et al., 2023. Association between the LRP1B and APOE loci and the development of Parkinson\u2019s disease dementia. Brain, 146(5): 1873\u20131887. https:\/\/doi.org\/10.1093\/brain\/awac414","journal-title":"Brain"},{"key":"854_CR81","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s40478-021-01282-8","volume":"9","author":"MJ Russo","year":"2021","unstructured":"Russo MJ, Orru CD, Concha-Marambio L, et al., 2021. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease. Acta Neuropathol Commun, 9:179. https:\/\/doi.org\/10.1186\/s40478-021-01282-8","journal-title":"Acta Neuropathol Commun"},{"key":"854_CR82","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00401-024-02706-0","volume":"147","author":"J Rutledge","year":"2024","unstructured":"Rutledge J, Lehallier B, Zarifkar P, et al., 2024. Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson\u2019s disease. Acta Neuropathol, 147:52. https:\/\/doi.org\/10.1007\/s00401-024-02706-0","journal-title":"Acta Neuropathol"},{"issue":"8","key":"854_CR83","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1038\/s41591-023-02440-2","volume":"29","author":"AK Schalkamp","year":"2023","unstructured":"Schalkamp AK, Peall KJ, Harrison NA, et al., 2023. Wearable movement-tracking data identify Parkinson\u2019s disease years before clinical diagnosis. Nat Med, 29(8):2048\u20132056. https:\/\/doi.org\/10.1038\/s41591-023-02440-2","journal-title":"Nat Med"},{"issue":"7","key":"854_CR84","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1474-4422(18)30169-8","volume":"17","author":"KA Schindlbeck","year":"2018","unstructured":"Schindlbeck KA, Eidelberg D, 2018. Network imaging bio-markers: insights and clinical applications in Parkinson\u2019s disease. Lancet Neurol, 17(7):629\u2013640. https:\/\/doi.org\/10.1016\/s1474-4422(18)30169-8","journal-title":"Lancet Neurol"},{"issue":"4","key":"854_CR85","doi-asserted-by":"publisher","first-page":"e93814","DOI":"10.1371\/journal.pone.0093814","volume":"9","author":"ST Schwarz","year":"2014","unstructured":"Schwarz ST, Afzal M, Morgan PS, et al., 2014. The \u2018swallow tail\u2019 appearance of the healthy nigrosome \u2013 a new accurate test of Parkinson\u2019s disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One, 9(4): e93814. https:\/\/doi.org\/10.1371\/journal.pone.0093814","journal-title":"PLoS One"},{"issue":"7","key":"854_CR86","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","volume":"22","author":"SH Shahmoradian","year":"2019","unstructured":"Shahmoradian SH, Lewis AJ, Genoud C, et al., 2019. Lewy pathology in Parkinson\u2019s disease consists of crowded organelles and lipid membranes. Nat Neurosci, 22(7):1099\u20131109. https:\/\/doi.org\/10.1038\/s41593-019-0423-2","journal-title":"Nat Neurosci"},{"issue":"2","key":"854_CR87","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","volume":"74","author":"M Shahnawaz","year":"2017","unstructured":"Shahnawaz M, Tokuda T, Waragai M, et al., 2017. Development of a biochemical diagnosis of Parkinson disease by detection of \u03b1-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol, 74(2):163\u2013172. https:\/\/doi.org\/10.1001\/jamaneurol.2016.4547","journal-title":"JAMA Neurol"},{"issue":"7794","key":"854_CR88","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz M, Mukherjee A, Pritzkow S, et al., 2020. Discriminating \u03b1-synuclein strains in Parkinson\u2019s disease and multiple system atrophy. Nature, 578(7794):273\u2013277. https:\/\/doi.org\/10.1038\/s41586-020-1984-7","journal-title":"Nature"},{"key":"854_CR89","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13024-018-0304-2","volume":"14","author":"YP Shao","year":"2019","unstructured":"Shao YP, Le WD, 2019. Recent advances and perspectives of metabolomics-based investigations in Parkinson\u2019s disease. Mol Neurodegener, 14:3. https:\/\/doi.org\/10.1186\/s13024-018-0304-2","journal-title":"Mol Neurodegener"},{"key":"854_CR90","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13024-021-00425-8","volume":"16","author":"YP Shao","year":"2021","unstructured":"Shao YP, Li TB, Liu ZY, et al., 2021. Comprehensive metabolic profiling of Parkinson\u2019s disease by liquid chromatographymass spectrometry. Mol Neurodegener, 16:4. https:\/\/doi.org\/10.1186\/s13024-021-00425-8","journal-title":"Mol Neurodegener"},{"issue":"5","key":"854_CR91","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant DE, et al., 2023. Assessment of heterogeneity among participants in the Parkinson\u2019s progression markers initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol, 22(5):407\u2013417. https:\/\/doi.org\/10.1016\/s1474-4422(23)00109-6","journal-title":"Lancet Neurol"},{"issue":"2","key":"854_CR92","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Chahine LM, Poston K, et al., 2024. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol, 23(2): 178\u2013190. https:\/\/doi.org\/10.1016\/s1474-4422(23)00405-2","journal-title":"Lancet Neurol"},{"issue":"3","key":"854_CR93","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ana.25824","volume":"88","author":"W Singer","year":"2020","unstructured":"Singer W, Schmeichel AM, Shahnawaz M, et al., 2020. Alpha-synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from Lewy body synucleinopathies. Ann Neurol, 88(3):503\u2013512. https:\/\/doi.org\/10.1002\/ana.25824","journal-title":"Ann Neurol"},{"issue":"4","key":"854_CR94","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/mds.27328","volume":"33","author":"W Song","year":"2018","unstructured":"Song W, Kothari V, Velly AM, et al., 2018. Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson\u2019s disease. Mov Disord, 33(4):583\u2013591. https:\/\/doi.org\/10.1002\/mds.27328","journal-title":"Mov Disord"},{"key":"854_CR95","doi-asserted-by":"publisher","first-page":"e080952","DOI":"10.1136\/bmj-2024-080952","volume":"388","author":"DN Su","year":"2025","unstructured":"Su DN, Cui YS, He CZ, et al., 2025. Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of global burden of disease study 2021. BMJ, 388:e080952. https:\/\/doi.org\/10.1136\/bmj-2024-080952","journal-title":"BMJ"},{"issue":"3","key":"854_CR96","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1148\/radiol.2015151466","volume":"279","author":"YH Sung","year":"2016","unstructured":"Sung YH, Noh Y, Lee J, et al., 2016. Drug-induced parkinsonism versus idiopathic Parkinson disease: utility of nigrosome 1 with 3-T imaging. Radiology, 279(3):849\u2013858. https:\/\/doi.org\/10.1148\/radiol.2015151466","journal-title":"Radiology"},{"issue":"2","key":"854_CR97","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1474-4422(10)70002-8","volume":"9","author":"CC Tang","year":"2010","unstructured":"Tang CC, Poston KL, Eckert T, et al., 2010. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol, 9(2):149\u2013158. https:\/\/doi.org\/10.1016\/s1474-4422(10)70002-8","journal-title":"Lancet Neurol"},{"issue":"5","key":"854_CR98","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa E, Garrido A, Scholz SW, et al., 2021. Challenges in the diagnosis of Parkinson\u2019s disease. Lancet Neurol, 20(5): 385\u2013397. https:\/\/doi.org\/10.1016\/s1474-4422(21)00030-2","journal-title":"Lancet Neurol"},{"issue":"10","key":"854_CR99","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/mds.27794","volume":"34","author":"K Tsukita","year":"2019","unstructured":"Tsukita K, Sakamaki-Tsukita H, Tanaka K, et al., 2019. Value of in vivo \u03b1-synuclein deposits in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord, 34(10): 1452\u20131463. https:\/\/doi.org\/10.1002\/mds.27794","journal-title":"Mov Disord"},{"key":"854_CR100","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13148-019-0621-5","volume":"11","author":"CL Wang","year":"2019","unstructured":"Wang CL, Chen L, Yang Y, et al., 2019. Identification of potential blood biomarkers for Parkinson\u2019s disease by gene expression and DNA methylation data integration analysis. Clin Epigenetics, 11:24. https:\/\/doi.org\/10.1186\/s13148-019-0621-5","journal-title":"Clin Epigenetics"},{"key":"854_CR101","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41746-024-01012-z","volume":"7","author":"J Wang","year":"2024","unstructured":"Wang J, Xue L, Jiang JH, et al., 2024. Diagnostic performance of artificial intelligence-assisted PET imaging for Parkinson\u2019s disease: a systematic review and meta-analysis. npj Digit Med, 7:17. https:\/\/doi.org\/10.1038\/s41746-024-01012-z","journal-title":"npj Digit Med"},{"issue":"6","key":"854_CR102","doi-asserted-by":"publisher","first-page":"afaf147","DOI":"10.1093\/ageing\/afaf147","volume":"54","author":"JY Wang","year":"2025","unstructured":"Wang JY, Song YD, Zhang DL, et al., 2025. Detection of early Parkinson\u2019s disease using 5-hydroxymethylcytosine episignatures in blood DNA. Age Ageing, 54(6):afaf147. https:\/\/doi.org\/10.1093\/ageing\/afaf147","journal-title":"Age Ageing"},{"issue":"1","key":"854_CR103","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaneurol.2020.3311","volume":"78","author":"ZR Wang","year":"2021","unstructured":"Wang ZR, Becker K, Donadio V, et al., 2021. Skin \u03b1-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease. JAMA Neurol, 78(1):30\u201340. https:\/\/doi.org\/10.1001\/jamaneurol.2020.3311","journal-title":"JAMA Neurol"},{"key":"854_CR104","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s40478-024-01873-1","volume":"12","author":"ZR Wang","year":"2024","unstructured":"Wang ZR, Gilliland T, Kim HJ, et al., 2024. A minimally invasive biomarker for sensitive and accurate diagnosis of Parkinson\u2019s disease. Acta Neuropathol Commun, 12:167. https:\/\/doi.org\/10.1186\/s40478-024-01873-1","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"854_CR105","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/brain\/awaa021","volume":"143","author":"EN Wilson","year":"2020","unstructured":"Wilson EN, Swarovski MS, Linortner P, et al., 2020. Soluble TREM2 is elevated in Parkinson\u2019s disease subgroups with increased CSF tau. Brain, 143(3):932\u2013943. https:\/\/doi.org\/10.1093\/brain\/awaa021","journal-title":"Brain"},{"issue":"7","key":"854_CR106","doi-asserted-by":"publisher","first-page":"2300285","DOI":"10.1002\/smtd.202300285","volume":"7","author":"W Xu","year":"2023","unstructured":"Xu W, Chen LN, Cai GE, et al., 2023. Diagnosis of Parkinson\u2019s disease via the metabolic fingerprint in saliva by deep learning. Small Methods, 7(7):2300285. https:\/\/doi.org\/10.1002\/smtd.202300285","journal-title":"Small Methods"},{"issue":"9","key":"854_CR107","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/mds.29497","volume":"38","author":"M Xylaki","year":"2023","unstructured":"Xylaki M, Chopra A, Weber S, et al., 2023. Extracellular vesicles for the diagnosis of Parkinson\u2019s disease: systematic review and meta-analysis. Mov Disord, 38(9):1585\u20131597. https:\/\/doi.org\/10.1002\/mds.29497","journal-title":"Mov Disord"},{"issue":"1","key":"854_CR108","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jamaneurol.2023.4398","volume":"81","author":"SJ Yan","year":"2024","unstructured":"Yan SJ, Jiang C, Janzen A, et al., 2024. Neuronally derived extracellular vesicle \u03b1-synuclein as a serum biomarker for individuals at risk of developing Parkinson disease. JAMA Neurol, 81(1):59\u201368. https:\/\/doi.org\/10.1001\/jamaneurol.2023.4398","journal-title":"JAMA Neurol"},{"issue":"3","key":"854_CR109","doi-asserted-by":"publisher","first-page":"101999","DOI":"10.1016\/j.xcrm.2025.101999","volume":"6","author":"SJ Yan","year":"2025","unstructured":"Yan SJ, Zhang WJ, Li XY, et al., 2025. Single extracellular vesicle detection assay identifies membrane-associated \u03b1-synuclein as an early-stage biomarker in Parkinson\u2019s disease. Cell Rep Med, 6(3):101999. https:\/\/doi.org\/10.1016\/j.xcrm.2025.101999","journal-title":"Cell Rep Med"},{"key":"854_CR110","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41531-024-00795-y","volume":"10","author":"BY Yang","year":"2024","unstructured":"Yang BY, Zhu YY, Li KL, et al., 2024. Machine learning model base on metabolomics and proteomics to predict cognitive impairment in Parkinson\u2019s disease. npj Parkinsons Dis, 10:187. https:\/\/doi.org\/10.1038\/s41531-024-00795-y","journal-title":"npj Parkinsons Dis"},{"key":"854_CR111","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41419-022-05531-z","volume":"14","author":"ZF Yang","year":"2023","unstructured":"Yang ZF, Wang Y, Wei M, et al., 2023. Intrastriatal injection of Parkinson\u2019s disease intestine and vagus lysates initiates \u03b1-synucleinopathy in rat brain. Cell Death Dis, 14:4. https:\/\/doi.org\/10.1038\/s41419-022-05531-z","journal-title":"Cell Death Dis"},{"key":"854_CR112","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev-pathmechdis-031521-034145","volume":"18","author":"H Ye","year":"2023","unstructured":"Ye H, Robak LA, Yu MG, et al., 2023. Genetics and pathogenesis of Parkinson\u2019s syndrome. Annu Rev Pathol Mech Dis, 18:95\u2013121. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-031521-034145","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"20","key":"854_CR113","doi-asserted-by":"publisher","first-page":"eadl6442","DOI":"10.1126\/sciadv.adl6442","volume":"10","author":"ZW Yu","year":"2024","unstructured":"Yu ZW, Zheng YC, Cai HH, et al., 2024. Molecular beacon-based detection of circulating microRNA-containing extracellular vesicle as an \u03b1-synucleinopathy biomarker. Sci Adv, 10(20):eadl6442. https:\/\/doi.org\/10.1126\/sciadv.adl6442","journal-title":"Sci Adv"},{"key":"854_CR114","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/s41597-024-03909-6","volume":"11","author":"ZY Yu","year":"2024","unstructured":"Yu ZY, Saiki S, Shiina K, et al., 2024. Comprehensive data for studying serum exosome microRNA transcriptome in Parkinson\u2019s disease patients. Sci Data, 11:1128. https:\/\/doi.org\/10.1038\/s41597-024-03909-6","journal-title":"Sci Data"},{"issue":"5","key":"854_CR115","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1021\/acscentsci.2c01468","volume":"9","author":"JD Zhang","year":"2023","unstructured":"Zhang JD, Xue CH, Kolachalama VB, et al., 2023. Interpretable machine learning on metabolomics data reveals biomarkers for Parkinson\u2019s disease. ACS Cent Sci, 9(5): 1035\u20131045. https:\/\/doi.org\/10.1021\/acscentsci.2c01468","journal-title":"ACS Cent Sci"},{"issue":"8","key":"854_CR116","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1007\/s00259-022-05804-x","volume":"49","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Wu P, Wu JJ, et al., 2022. Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning. Eur J Nucl Med Mol Imaging, 49(8):2798\u20132811. https:\/\/doi.org\/10.1007\/s00259-022-05804-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"854_CR117","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1002\/mds.29828","volume":"39","author":"YC Zheng","year":"2024","unstructured":"Zheng YC, Yu ZW, Cai HH, et al., 2024. Detection of \u03b1-synuclein in oral mucosa by seed amplification assay in synucleinopathies and isolated REM sleep behavior disorder. Mov Disord, 39(8):1300\u20131309. https:\/\/doi.org\/10.1002\/mds.29828","journal-title":"Mov Disord"},{"key":"854_CR118","doi-asserted-by":"publisher","first-page":"567386","DOI":"10.1155\/2015\/567386","volume":"2015","author":"B Zhou","year":"2015","unstructured":"Zhou B, Wen M, Yu WF, et al., 2015. The diagnostic and differential diagnosis utility of cerebrospinal fluid \u03b1-synuclein levels in Parkinson\u2019s disease: a meta-analysis. Parkinsons Dis, 2015:567386. https:\/\/doi.org\/10.1155\/2015\/567386","journal-title":"Parkinsons Dis"}],"container-title":["Journal of Zhejiang University-SCIENCE B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2500789.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1631\/jzus.B2500789","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2500789.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:03:19Z","timestamp":1785834199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1631\/jzus.B2500789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":118,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["854"],"URL":"https:\/\/doi.org\/10.1631\/jzus.b2500789","relation":{},"ISSN":["1673-1581","1862-1783"],"issn-type":[{"value":"1673-1581","type":"print"},{"value":"1862-1783","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Xiang LI, Honglin CHEN, Xu WANG, Yuhe HU, Zhaofei YANG, and Min WEI declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"This review does not contain any studies with human or animal subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}